Avid Radiopharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Avid Radiopharmaceuticals sits in the top decile of US sponsors by registered trial count (#420 of 15,742 sponsors by registered trial count).
Avid Radiopharmaceuticals: 42 sponsored US clinical trials, none currently recruiting.
Avid Radiopharmaceuticals sponsors 42 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 37 completed. 9 of these trials are in Phase 3-4 (later-stage) and 32 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Alzheimers Disease, with 3 trials.
Top-decile sponsor footprint
Avid Radiopharmaceuticals ranks in the top decile of sponsors by registered trial count (#420 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
37 of 42 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
42 total, page 1 of 1
18F-LY3950321-01 Biodistribution and Safety Study
NCT05775601
Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease
NCT03901105
A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation
NCT03901092
Tau Screening Study in Subjects With Early Symptomatic AD
NCT03467477
Tau Screening Study in Patients With Early Symptomatic AD
NCT03322462
Flortaucipir PET Imaging in Subjects With FTD
NCT03040713
Flortaucipir 18F PET Imaging in BIOCARD Study
NCT03052972
18F-AV-1451 High Resolution Autopsy Study
NCT02350634
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
NCT02918539
Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05
NCT02795780
18F-AV-1451 Autopsy Study
NCT02516046
Tau Imaging in Professional Fighters
NCT02278354
Augmenting Flortaucipir Dosimetry Estimates
NCT02336360
Clinical Evaluation of Flortaucipir F 18
NCT02278367
Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers
NCT02167594
18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy
NCT02079766
Imaging Characteristics of a Follow-up 18F-AV-1451 Scan
NCT02051764
Florbetapir Calibration to the Centiloid Scale
NCT02120664
Evaluation of Reader Training Processes
NCT02051790
Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects
NCT02016560
A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired Subjects
NCT01992380
Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects
NCT04474405
The Feasibility of Florbetapir Quantitation
NCT01946243
Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls
NCT01710371
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
NCT01703702
A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808
NCT01723488
A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807
NCT01733355
A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders
NCT01550484
Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline
NCT01400425
A Trial of 18F-AV-133 Positron Emission Tomography (PET)
NCT01515384
A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)
NCT01503944
Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07
NCT01447719
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
NCT01518374
Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals
NCT00855868
Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients
NCT00857532
Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)
NCT00857506
Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain
NCT00857415
A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
NCT00702143
A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers
NCT01565343
A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers
NCT01565330
A Study of 18F-AV-45 in Healthy Volunteers
NCT01564706
A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers
NCT01565291
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 19 |
| Phase 2 | 13 |
| Phase 3 | 6 |
| Phase 4 | 3 |
Therapeutic Areas
How the Avid Radiopharmaceuticals early-phase archive is shaped
42 indexed studies, none listed as recruiting (0% open); 37 completed (88%).
Phase mix: 9 late (III/IV) vs 32 early (I/II) (early-phase heavy).
Top condition: Alzheimers Disease (3 trials), 4 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Avid Radiopharmaceuticals: archived-pipeline peers nationwide
Peers matched on 42 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Avid Radiopharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 42 archived trials
- Academic and Community Cancer Research United · 42 trials · 14% recruiting
- Ascensia Diabetes Care · 42 trials · 0% recruiting
- Celldex Therapeutics · 42 trials · 7% recruiting
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 42 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Avid Radiopharmaceuticals page
42 registered trials is a research-attention snapshot, not an endorsement of Avid Radiopharmaceuticals or any single study.
- None of Avid Radiopharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Alzheimers Disease is the condition Avid Radiopharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Alzheimers Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Avid Radiopharmaceuticals pipeline card: 42 registered trials from official public datasets.Report a data error.